Arhiv za farmaciju (Jan 2022)

Molecular biomarkers in multiple sclerosis

  • Michaličková Danica,
  • Kübra Öztürk Hatice,
  • Das Debanjan,
  • Osama Bukhari Syed,
  • Slanař Ondřej

DOI
https://doi.org/10.5937/arhfarm72-36165
Journal volume & issue
Vol. 72, no. 2
pp. 127 – 148

Abstract

Read online

Multiple sclerosis (MS) is a highly heterogenous disease regarding radiological, pathological, and clinical characteristics and therapeutic response, including both the efficacy and safety profile of treatments. Accordingly, there is a high demand for biomarkers that sensitively and specifically apprehend the distinctive aspects of the MS heterogeneity, and that can aid in better understanding of the disease diagnosis, prognosis, prediction of the treatment response, and, finally, in the development of new treatments. Currently, clinical characteristics (e.g., relapse rate and disease progression) and magnetic resonance imaging play the most important role in the clinical classification of MS and assessment of its course. Molecular biomarkers (e.g., immunoglobulin G (IgG) oligoclonal bands, IgG index, anti-aquaporin-4 antibodies, neutralizing antibodies against interferon-beta and natalizumab, anti-varicella zoster virus and anti-John Cunningham (JC) virus antibodies) complement these markers excellently. This review provides an overview of exploratory, validated and clinically useful molecular biomarkers in MS which are used for prediction, diagnosis, disease activity and treatment response.

Keywords